Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)

Jonathan I. Silverberg; Mette Deleuran; Linda S. Gold; Christopher G. Bunick; Dirk Jan Hijnen; Brian M. Calimlim; Henrique D. Teixeira; Andrew M. Platt; Ayman Grada; Xiaofei Hu; Melinda Gooderham

Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)

Jonathan I. Silverberg
, Mette Deleuran
, Linda S. Gold
, Christopher G. Bunick
, Dirk Jan Hijnen
, Brian M. Calimlim
, Henrique D. Teixeira
, Andrew M. Platt
, Ayman Grada
, Xiaofei Hu
, Melinda Gooderham

Dermatology

George Washington University
Aarhus University
Henry Ford Health System
Yale University
AbbVie
Queens University - Canada

Research output: Contribution to journal › Meeting Abstract › Academic › peer-review

Original language	English
Pages (from-to)	AB90-AB90
Number of pages	1
Journal	Journal of the American Academy of Dermatology
Volume	89
Issue number	3
Publication status	Published - Sept 2023
Event	Annual Meeting of the American-Academy-of-Dermatology (AAD) - New Orleans, Lao People's Democratic Republic Duration: 17 Mar 2023 → 21 Mar 2023

Cite this

Silverberg, J. I., Deleuran, M., Gold, L. S., Bunick, C. G., Hijnen, D. J., Calimlim, B. M., Teixeira, H. D., Platt, A. M., Grada, A., Hu, X., & Gooderham, M. (2023). Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up). Journal of the American Academy of Dermatology, 89(3), AB90-AB90.

Silverberg, Jonathan I. ; Deleuran, Mette ; Gold, Linda S. et al. / Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis : Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up). In: Journal of the American Academy of Dermatology. 2023 ; Vol. 89, No. 3. pp. AB90-AB90.

@article{d6f86cdaaedd4f35a1833b72cfd68277,

title = "Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)",

author = "Silverberg, \{Jonathan I.\} and Mette Deleuran and Gold, \{Linda S.\} and Bunick, \{Christopher G.\} and Hijnen, \{Dirk Jan\} and Calimlim, \{Brian M.\} and Teixeira, \{Henrique D.\} and Platt, \{Andrew M.\} and Ayman Grada and Xiaofei Hu and Melinda Gooderham",

year = "2023",

month = sep,

language = "English",

volume = "89",

pages = "AB90--AB90",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "3",

note = "Annual Meeting of the American-Academy-of-Dermatology (AAD) ; Conference date: 17-03-2023 Through 21-03-2023",

}

Silverberg, JI, Deleuran, M, Gold, LS, Bunick, CG, Hijnen, DJ, Calimlim, BM, Teixeira, HD, Platt, AM, Grada, A, Hu, X & Gooderham, M 2023, 'Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)', Journal of the American Academy of Dermatology, vol. 89, no. 3, pp. AB90-AB90.

Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up). / Silverberg, Jonathan I.; Deleuran, Mette; Gold, Linda S. et al.
In: Journal of the American Academy of Dermatology, Vol. 89, No. 3, 09.2023, p. AB90-AB90.

Research output: Contribution to journal › Meeting Abstract › Academic › peer-review

TY - JOUR

T1 - Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis

T2 - Annual Meeting of the American-Academy-of-Dermatology (AAD)

AU - Silverberg, Jonathan I.

AU - Deleuran, Mette

AU - Gold, Linda S.

AU - Bunick, Christopher G.

AU - Hijnen, Dirk Jan

AU - Calimlim, Brian M.

AU - Teixeira, Henrique D.

AU - Platt, Andrew M.

AU - Grada, Ayman

AU - Hu, Xiaofei

AU - Gooderham, Melinda

PY - 2023/9

Y1 - 2023/9

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:001078492800351&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0190-9622

VL - 89

SP - AB90-AB90

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 3

Y2 - 17 March 2023 through 21 March 2023

ER -

Sustained Improvement Over 52 Weeks in Patient-Reported Itch, Symptoms, and Quality of Life With Upadacitinib in Patients With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)

Other files and links

Cite this